Related Experiment Videos

Tamoxifen and the gynaecologist

P Neven¹, J H Shepherd, D G Lowe

¹Algemene Kliniek St Jan, Dienst Gynaecologie en Verloskunde, Brussels, Belgium.

British Journal of Obstetrics and Gynaecology

|October 1, 1993

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.

ESMO open·2026

Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.

ESMO open·2026

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study.

ESMO open·2026

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Overall survival with abemaciclib in early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

See all related articles